Private Label Cosmetics Contracts: 8 Clauses to Lock Down Before You Sign (2026 MoCRA & CPNP Edition)

A two-page manufacturing agreement is not a sign of simplicity. It is a sign that nobody has decided who pays when things go wrong.

Why the contract — not the price sheet — decides your margin

When founders compare private label cosmetics manufacturers, the conversation almost always collapses into unit cost. Factory A quotes $2.40 a unit, Factory B quotes $2.15, and the decision gets made on twenty-five cents.

That is the wrong variable. Twenty-five cents on a 5,000-unit run is $1,250. A formula ownership clause written the wrong way can cost you the entire product line.

Under the Modernization of Cosmetics Regulation Act (MoCRA), US brands now carry obligations that simply did not exist before 2023 — facility registration, product listing, safety substantiation, and adverse event recordkeeping. In the EU, Regulation 1223/2009 requires a named Responsible Person established in the Union before a single unit can be notified through CPNP. Both regimes create a question your contract must answer explicitly: who does this work, and who pays for it?

Most template agreements circulating in the industry were written before MoCRA existed. That is the gap this guide closes.

---

The 8 clauses

1. Formula ownership and IP assignment

This is the one that ends brands.

Founders assume that paying for development means owning the output. In most jurisdictions it does not. Absent an explicit written assignment, the party that authored the formulation typically retains rights to it — and that party is the factory's chemist.

You need three distinct layers spelled out:

Negotiation script: "Our formulation is the core asset behind our raise. We need explicit assignment language. If your standard agreement doesn't include it, we're comfortable adding it as an annex — this is standard practice with the contract manufacturers used by brands like The Ordinary and Hero Cosmetics."

Red flag: "Everyone signs it like this, it's fine." That sentence is itself the reason to slow down.

A distinction worth understanding: if the factory brings a pre-existing stock base to the table and you only customise fragrance and colour, you are buying a licence, not ownership — and you should not pay ownership prices for it. Be honest about which of the two you are actually doing, and price accordingly.

---

2. MOQ and flexibility mechanics

Low MOQ cosmetic manufacturing is the single most-searched requirement among first-time brands, and the single most loosely drafted clause.

The number in the quote is not the number in the contract unless you make it so. Four things need to be nailed down:

Negotiation script: "We want to validate demand before committing capital. Can we run the first batch at 500 units? If it sells through, we'll move to 2,000+ on the reorder — we're not looking for a one-off."

---

3. Lead times and delay remedies

"30 days" is meaningless until you define day zero.

Thirty days from PO? From deposit clearing? From component arrival? From safety assessment sign-off? Those four anchors can sit two months apart.

Define three:

1. T0 — agreement executed, deposit received
2. T1 — all raw materials and packaging components physically at the factory
3. T2 — finished goods released, CoA and batch documentation issued

Then attach consequences:

• Delay of ≤7 days past T2 → manufacturer absorbs storage costs
• Delay >7 days → liquidated damages at 0.1–0.3% of order value per day
• Delay >30 days → brand may terminate and recover deposit

Write the symmetrical case too. If your artwork approval slips three weeks, T2 should move. Contracts that only bind one side rarely survive contact with reality.

---

4. Quality standards and non-conforming goods

"We test everything" is not a specification. Name the standards.

Then define what happens when a batch fails: rework at whose cost, who pays return freight, who funds the retest, and — critically — who bears the cost of a market withdrawal. MoCRA's adverse event recordkeeping requirement makes this last point far more concrete than it used to be.

---

5. Price validity and adjustment triggers

Raw material volatility is real. Niacinamide, hyaluronic acid and specialty peptides routinely swing 10–30% year over year. The problem is not that factories raise prices; it is that most contracts let them do so at will.

Structure it:

Quoted price valid: 6 months from execution
Adjustment trigger: verified raw material movement exceeding ±15%
Adjustment process: 30 days written notice + supporting purchase documentation
Adjustment cap: 10% per event, 20% cumulative per contract year
Downward symmetry: price reductions apply when input costs fall

That last line matters. Adjustment clauses drafted by factories are almost always one-directional.

---

6. Formula change control and right to know

Can the factory substitute a raw material supplier without telling you?

Under most standard agreements: yes. And it happens constantly — usually for legitimate supply reasons, occasionally for margin.

Require:

• Written brand approval for any formulation change, including supplier substitution of an identical INCI
• Advance notice plus alternative options where a change is driven by regulatory action
• Updated full INCI declaration and safety assessment following any change

Why supplier identity matters: two suppliers can both ship sodium hyaluronate meeting the same INCI and the same percentage, with different molecular weight distributions. The label is identical. The skin feel is not. Consumers notice, reviews reflect it, and you will spend weeks diagnosing a problem your contract could have prevented.

---

7. Confidentiality — broader than the formula

Most NDAs cover technical information and stop there. Extend the scope:

• Sales velocity, channel mix, retailer terms
• Launch timing and pricing strategy
• The existence of the relationship itself — many brands do not disclose their contract manufacturer, and factory case studies have outed more than one

Practical terms: survival of 3–5 years post-termination, explicit carve-outs for legally compelled disclosure and genuinely public information, and a remedy that is actually enforceable rather than "damages as determined by law."

---

8. Termination and exit

Every relationship ends. The contract should describe the ending while both parties still like each other.

Tooling is the trap. If you paid for the mould, say that you own it. If the factory absorbed the cost as a volume incentive, they usually own it — and you will discover this at the worst possible moment.

---

The MoCRA and CPNP question your contract must answer

This is where US and EU brands get caught, and where most Asia-sourced template agreements are silent.

Write a single clause titled Regulatory Cooperation that obliges the manufacturer to supply, within a fixed number of business days, every document a Responsible Person needs. Without it, you will be chasing a PIF by email while your CPNP notification sits blocked and your launch date moves.

---

Pre-signature checklist

Legal

• [ ] Formula IP assigned in writing (ownership + exclusivity + personnel restriction)
• [ ] Confidentiality covers technical and commercial information
• [ ] Liability provisions are specific and enforceable
• [ ] Governing law and dispute forum named — arbitration is usually faster for cross-border

Commercial

• [ ] MOQ stated numerically with first-order flexibility
• [ ] T0 / T1 / T2 anchors defined, delay remedies attached
• [ ] Quality standards reference ISO 22716 and named test methods
• [ ] Price validity window, adjustment trigger and cap all present

Regulatory

• [ ] Facility registration warranty (MoCRA) with FEI number
• [ ] Product Information File deliverable defined for CPNP
• [ ] Document turnaround SLA for regulatory requests
• [ ] Batch traceability cooperation for adverse event reporting

---

Three ways founders lose money here

"That's just our standard template." Volume of use is not evidence of fairness. It is evidence that previous customers had less leverage than you think you have.

Verbal commitments that never made it into the document. "Sales said the MOQ was flexible." Sales is not a party to the agreement. Get it in the contract or, at minimum, in an email chain the contract incorporates by reference.

Optimising the unit price while ignoring the terms. Saving $0.25 a unit is worthless if the formula belongs to the factory, delays carry no remedy, and the quality spec is "as agreed." Price is the most visible term and rarely the most expensive one.

---

On marketing claims — a note for the substantiation file

If a factory offers to supply "clinically proven" claims alongside the formulation, ask for the study protocol before you use anything. Panel size, control conditions, instrumentation and duration determine whether a claim will survive a challenge. Under MoCRA, safety substantiation is your legal obligation regardless of who generated the data — a supplier's marketing deck is not a substantiation file.

---

🔗 Reviewing an OEM agreement, or preparing to negotiate one? QuickOEM works with brands on formulation ownership terms, MOQ structuring, and MoCRA/CPNP documentation packages. → https://www.quickoem.com/en/contact